Bitopertin Hits All End Points in Phase 3 APOLLO Trial for EPP
Bitopertin met all end points in the Phase 3 APOLLO trial for erythropoietic protoporphyria, a rare light-pain disorder with no approved U.S. systemic therapy.
Topic
Bitopertin
Topic
Topic
Topic
Bitopertin met all end points in the Phase 3 APOLLO trial for erythropoietic protoporphyria, a rare light-pain disorder with no approved U.S. systemic therapy.